Citations

Clear

867 citation(s) found for "Moore, W C".

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer
Barlow, William E. , Moore, Halle C F, Hobday, T., Isaacs, Claudine, Salim, Muhammad , Albain, Kathy S. , Chew, Helen K. , Burton, G., Srkalović, Gordan , Flaherty, Lawrence E. , Lew, Danika L., Hortobagyi, Gabriel N, Sharma, Priyanka, Pusztai, Lajos, Budd, George T, Moore, Halle C. F. , Isaacs, Claudine , Ali, Azka , Barlow, William E , Moore, Halle C F , Isaacs, Claudine , Albain, Kathy , Srkalovic, Gordan , McGregor, Bradley , Gralow, Julie R , Sharma, Priyanka , Pusztai, Lajos , Budd, G Thomas , Hobday, Timothy J. , McGregor, Bradley A. , Gralow, Julie R. , Hortobágyi, Gabriel N. , Sharma, Priyanka , Pusztai, Lajos , Budd, G. Thomas

Mayo Clinic

JNCI Cancer Spectrum | March 12, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/jncics/pkag024 | PMID 41832961 Get It

Abstract Background S0221 investigated weekly vs every 2 weeks dosing of doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel in patients with high-risk early breast cancer. After an interim analysis, random assignment to the 2 AC arms was stopped for futility, and the trial was modified to study only the paclitaxel schedules. Methods Between December 2003 and November 2010, a total of 2716 patients were randomly assigned in a 2 × 2 factorial design to 15 weeks of weekly A and daily C vs 6 cycles of every 2 weeks AC; and weekly paclitaxel for 12 weeks vs 6 cycles of every 2 weeks paclitaxel. Between January 2011 and January 2012, an additional 578 patients were assigned to 4 cycles of every 2 weeks AC and randomly assigned to weekly vs every 2 weeks paclitaxel. Updated survival was assessed using log-rank tests and Cox regression models. We compared outcomes by breast cancer subtype as well. Results At a median follow-up of 12.1 years, there were no statistically significant differences among the 4 treatment arms in disease-free survival (DFS) (P = .91) or overall survival (P = .34) in the original protocol. Among the 578 patients assigned AC for 4 cycles and randomly assigned to paclitaxel weekly vs every 2 weeks paclitaxel, there were no overall differences in DFS (P = .32) or overall survival (P = .42). Conclusion As there were no statistically significant outcome differences in DFS or overall survival between the studied schedules of AC and paclitaxel with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.
Editorial Commentary : A Signal Through the Noise: Platelet‐Rich Plasma's Promise for Extra‐articular Hip Pathology
Brinkman, Joseph C. , Moore, M. Lane, Moore, M. Lane , Moore, M Lane , Chahla, Jorge

Mayo Clinic

Arthroscopy | March 12, 2026 | Volume: 42 | Issue: 1 | Pages: 326-328

10.1002/arj.70045 | PMID 41838557 Get It

Abstract Platelet‐rich plasma (PRP) continues to generate both excitement and skepticism within orthopaedics and sports medicine. As a biologic derived from autologous blood, PRP offers an appealing, minimally invasive option for treating musculoskeletal pathology through the delivery of concentrated growth factors and cytokines. Evidence across orthopaedic subspecialties remains mixed, however, with studies showing variable efficacy and inconsistent methodologies. Recent data on PRP use for extra‐articular hip pathology, particularly greater trochanteric pain syndrome, hamstring injuries, and piriformis syndrome show encouraging improvements in pain and function, including faster return to sport and favorable patient‐reported outcomes. Yet, significant heterogeneity in study design, PRP preparation, and control interventions limits generalizability and hinders clear clinical guidance. These inconsistencies mirror similar challenges in PRP research for a variety of other orthopaedic pathologies, underscoring the need for standardized preparation protocols and consistent reporting frameworks. Despite these limitations, a signal of efficacy persists within the data, suggesting PRP may indeed provide meaningful benefit for select extra‐articular hip conditions. As surgical alternatives for these pathologies often carry substantial morbidity, continued refinement of PRP formulations and methodology represents a promising step toward establishing biologics as reliable, evidence‐based tools in orthopaedic care.
Unintended prolonged opioid use: a prospective case–control study
Hooten, W. Michael , Erickson, Darin J. , Scholz, N. , Waljee, Jennifer F., Brummett, Chad M., Jeffery, Molly M., Chawarski, Marek Cezary , Waljee, Jennifer F. , Brummett, Chad M. , Jeffery, Molly Moore

Mayo Clinic

Pain | March 9, 2026 | Volume: 167 | Issue: 6 | Pages: e180-e190

10.1097/j.pain.0000000000003945 | PMID 41800757 Get It

Abstract Appropriate short-term use of opioids in opioid-naive adults can result in unintended prolonged opioid use (UPOU) which is associated with significant morbidity and mortality. The objective of this prospective case–control study was to identify incident cases of UPOU and to compare their characteristics with patients who did not progress to UPOU. Opioid-naive adults receiving an initial opioid prescription for surgical or nonsurgical indications were recruited at 3 clinical sites. Patients progressing to UPOU (cases) were identified 90 days after the initial prescription and compared with patients who did not progress to UPOU (controls). The status of opioid use was verified using urine drug tests. The cohort included 513 cases and 517 controls. The mean (SD) patient age was 49.6 (15.3) years and 694 (67.4%) were female. In an adjusted logistic regression analysis, several patient characteristics significantly associated with UPOU included ≥2 emergency department evaluations in the past year; prior spine, joint replacement, or cataract surgery; status as a current or former smoker; daily use of over-the-counter pain medications; opioid craving; and greater pain interference. Conversely, characteristics negatively associated with UPOU included postsurgical pain as the indication for the initial opioid prescription, prior pregnancy, greater widespread body pain, and lower levels of general activity. The findings of this study offer novel insights into the behavioral pain responses and patient characteristics associated with UPOU. These results will be used to promote strategies to identify at-risk patients and to deploy interventions targeting the modifiable risk factors for UPOU.
Comparing the Efficacy Between ChatGPT 5, Grok 3, and Claude 4.5 Sonnet in Analyzing Orthopedic Trauma-Related Imaging
Holmstrom, Joshua Aaron , Braithwaite, Collin , Alhankawi, Ahmad R. , Moore, M. Lane, Patel, Karan A. , Miller, Brian H., Moore, M. Lane , Alhankawi, Ahmad R. , Holmstrom, Joshua A , Braithwaite, Collin L , Moore, M Lane , Patel, Karan

Mayo Clinic

Journal of Orthopaedic Trauma | March 5, 2026 | Volume: 40 | Issue: 7 | Pages: 360-365

10.1097/bot.0000000000003166 | PMID 41785426 Get It

OBJECTIVES: To evaluate and compare the ability of three popular open-source artificial intelligence platforms to diagnose common trauma-related fractures using radiologic imaging. METHODS: Design: Retrospective diagnostic performance comparison study. Setting: Publicly accessible online radiologic imaging databases. Patient Selection Criteria: Five common orthopedic trauma fractures were assessed: ankle, tibial plateau, intertrochanteric, femoral neck, and humerus. Radiographs and computed tomography (CT) images were collected. Images were randomly selected from confirmed diagnoses on Radiopaedia.org. Outcome Measures and Comparisons: ChatGPT 5, Grok 3, and Claude 4.5 Sonnet were queried with each image. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values, and performance by modality (X-ray vs. CT) were assessed. The reference standard was the expert-verified diagnosis provided by Radiopaedia.org, limited to cases labeled with a “diagnosis certain” tag. RESULTS: Each model was provided with 30 radiographs and 20 CT images whenever possible. ChatGPT 5, Grok 3, and Claude 4.5 Sonnet accurately diagnosed diseased images in 26.8%, 18.8%, and 22.4% of cases, respectively. By fracture type, ChatGPT 5 demonstrated the highest correct classification rates for ankle (10%), femoral neck (38%), humerus (40%), and tibial plateau (44%) fractures. Grok 3 demonstrated the highest correct classification rate for intertrochanteric fractures (6%). Overall sensitivities were 0.267, 0.187, and 0.223 for ChatGPT 5, Grok 3, and Claude 4.5 Sonnet, respectively. ChatGPT 5 and Grok 3 outperformed Claude 4.5 Sonnet (both P < 0.001). No modality-based performance differences were observed for any model. CONCLUSIONS: Among the publicly available large language models evaluated for radiologic interpretation of orthopedic trauma imaging, ChatGPT 5 demonstrated the highest overall diagnostic accuracy, followed by Claude 4.5 Sonnet and Grok 3. Despite relative variation between the models, overall diagnostic accuracy for fracture detection was low across all platforms (<27%). In their baseline forms, these publicly accessible large language models are not recommended for radiologic imaging interpretation. LEVEL OF EVIDENCE: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Surgical Pathology of Diffuse Parenchymal Lung Disease in Adults With IgA Vasculitis or IgA Nephropathy
Moore, Samantha A. , Butt, Yasmeen M. , Tazelaar, Henry D. , Larsen, Brandon T. , Smith, Maxwell L. , Tazelaar, Henry D.

Mayo Clinic

American Journal of Surgical Pathology | March 2, 2026 | Volume: 50 | Issue: 5 | Pages: 579-588

10.1097/pas.0000000000002522 | PMID 41765695 Get It

IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are closely related disorders that usually present in childhood. Pulmonary involvement is rare and histopathologic features thereof in adults are poorly understood. Institutional archives were searched for adults with IgAV or IgAN and diffuse parenchymal lung disease. Ten patients (6 men, median age 59 years) with lung tissue sampling were enrolled. Clinical history and pathology slides were reviewed. All patients were diagnosed with IgAV or IgAN before or concurrently with lung disease. Symptoms were nonspecific but hemoptysis was common. Radiologically, bilateral ground-glass opacities, consolidation, and reticulonodular densities were typical. Histologically, 6 cases (60%) featured acute or subacute diffuse alveolar hemorrhage (DAH) accompanied by definite (40%) or probable (20%) capillaritis. Two cases (20%) featured resolved DAH only, manifesting as alveolar hemosiderosis without other changes. And 2 cases featured organizing pneumonia without DAH. Five patients had a chronic interstitial pneumonia in the background, including 3 with nonspecific interstitial pneumonia (NSIP) and 2 with unclassifiable fibrosis. Findings were similar in IgAV versus IgAN. Of 4 patients with follow-up information, 2 died during hospitalization, one died 9 weeks later of secondary complications, and one was treated with rituximab and nintedanib and is alive 2 years later. To our knowledge, this is the largest series detailing pulmonary histopathologic findings in adults with IgAV or IgAN. Most cases show acute DAH with capillaritis; less commonly, old DAH, organizing pneumonia, NSIP, or unclassifiable fibrosis may be observed. Some patients do well with treatment but fatal cases also occur.
Molecular landscape of prostate cancers with clival metastases
Likasitwatanakul, Pornlada , Blinka, Steven , Zarka, Jabra , Gebrael, Georges , Weg, Emily S. , Longoria, Ossian , Moore, Joseph A , Sharp, Adam , Bono, Johann de, Sternberg, Cora N, Agarwal, Neeraj, Swami, Umang , Orme, Jacob J. , Schweizer, Michael T. , Hwang, Justin H, Antonarakis, Emmanuel S, Bono, Johann S. de , Antonarakis, Emmanuel S. , Hwang, Justin H. , Gebrael, Georges , Antonarakis, Emmanuel S. , Blinka, Steven M , Zarka, Jabra G , Weg, Emily , de Bono, Johann , Agarwal, Archana M , Sloan, Lindsey , Hwang, Justin H , Antonarakis, Emmanuel S , Antonarakis, Emmanuel S , Sternberg, Cora N , Agarwal, Neeraj

Mayo Clinic

The Oncologist | March 1, 2026 | Volume: 31 | Issue: 4 | Pages: No page available

10.1093/oncolo/oyag074 | PMID 41782345 Get It

Abstract Background Clival metastases are a rare and clinically aggressive manifestation of advanced prostate cancer, associated with cranial nerve palsy and poor survival. The molecular features of prostate cancers giving rise to clivus metastases remain unknown. Patients and methods We performed a multi-center retrospective study across six institutions, identifying prostate cancer patients with radiographically confirmed clival metastases and available next-generation sequencing (NGS) data. Baseline characteristics and clinical outcomes were collected. Genomic alterations from tissue- and/or blood-based assays were aggregated at the patient level and compared with a publicly available metastatic castration-resistant prostate cancer (mCRPC) cohort (SU2C/PCF). Results Fifty-nine patients with clival metastases contributed 87 molecular assays. More than half of patients had Gleason grade group 5 cancer and presented with de novo metastatic (M1) disease. The median interval from initial prostate cancer diagnosis to clival metastasis was 71.4 months (95% CI, 42.0-101.7), while median overall survival following clival involvement was only 15.3 months (95% CI, 6.9-22.8). Compared with the SU2C/PCF mCRPC cohort, clival metastases showed significant enrichment of BRAF and CHEK2 alterations as well as homologous recombination repair (HRR) with relative depletion of AR-related, PI3K pathway, and G2–M pathway alterations. Conclusion Prostate cancers giving rise to clival metastases exhibit a distinct molecular profile enriched for DNA damage–repair and RAF kinase alterations, suggesting unique metastatic biology and potential therapeutic vulnerabilities.
Impact of Calvarial Burring in Squamous Cell Carcinoma of the Scalp Without Gross Calvarial Involvement
Baratz, Hannah , Schmidtman, Daniel C. , Moore, E.J., Tasche, K., Abel, Kathryn M. Van , Baratz, Hannah Q , Yin, Linda X , Tasche, Kendall K. , Van Abel, Kathryn M , Schmidtman, Daniel C , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 28, 2026 | Volume: 135 | Issue: 7 | Pages: 530-534

10.1177/00034894261419886 | PMID 41761567 Get It

Background: To compare oncologic and postoperative outcomes in patients with scalp squamous cell carcinoma with periosteal, but not gross calvarial, involvement, treated with margin-clearing excision including either calvarial burring or periosteal excision alone. Study Design: Retrospective cohort study. Setting: Single tertiary academic referral center. Methods: We retrospectively reviewed surgical cases from January 2001 to January 2025. Inclusion criteria: patients ≥18 years with biopsy-proven scalp squamous cell carcinoma involving the periosteum without cortical invasion on imaging. Management of the deep margin included either burring of the outer table or periosteal excision alone. Demographic, surgical, and oncologic outcomes were collected and analyzed descriptively. Results: Twenty patients met inclusion criteria. Median age was 70 (range 56-92), and 18 (86%) were male. Thirteen (65%) patients underwent calvarial burring, 7 (35%) underwent periosteal excision. Local recurrence occurred in 31% and 29% of the burring group and non-burring group. Disease-free survival at 2 years was 46% and 57% in the burring and non-burring group, respectively. Overall survival at 2 years was 77% and 86% in the burring and non-burring group. Three patients in the burring group had local recurrences with intracranial extension, 1 died of disease, 1 died with disease and concurrent meningitis, 1 is alive with disease recurrence currently on palliative treatment. There were 7 disease-related deaths. Conclusion: Burring did not confer a significant oncologic advantage compared to periosteal excision alone when there was no gross cortical invasion. Local recurrence in patients undergoing calvarial burring was associated with intracranial extension of disease.
Impact of Tumor Vascularity and Extent of Embolization on Surgical Outcomes in Juvenile Nasopharyngeal Angiofibroma
Aden, Hafsa D., Stokken, Janalee K, Wiedermann, Joshua P. , Moore, E.J., O'Brien, Erin K., Gompel, J. Van, Brinjikji, Waleed, Hj, Cloft, Zalaquett, Nader , Olson, Brennan , Eide, Jacob G. , Gompel, Jamie J. Van , Brinjikji, Waleed , Cloft, Harry J. , Pinheiro‐Neto, Carlos

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1819390 Get It

Impact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study
Haidar, Lara, Crane, Heidi M, Nance, Robin M., Bamford, Laura, Burkholder, Greer, Cachay, Edward, Christopoulos, Katerina, Commanday, Alexander, Aboulatta, Laila, Delaney, J A C, Fahey, Carolyn, Heath, S. S., Kalayjian, Robert, Kitahata, Mari M, Kyle, Ryan, Mayer, K., Moore, Richard D, Pettit, April C, Napravnik, Sonia, Saag, M. S., Willig, Amanda L., Whitney, Bridget M. , Kyle, Ryan P. , Eltonsy, Sherif , Haidar, Lara, Crane, Heidi M. , Nance, Robin M. , Doupe, Malcolm Bray , Leong, Christine , Burkholder, Greer , Cachay, Edward R. , Christopoulos, Katerina A. , Delaney, Joseph A. , Drumright, Lydia N. , Kalayjian, Robert C. , Kitahata, Mari M. , Kyle, Ryan P., Moore, Richard D. , Pettit, April Christine , Napravnik, Sonia , Ruderman, Stephanie A. , Willig, Amanda L

Mayo Clinic

JAIDS Journal of Acquired Immune Deficiency Syndromes | February 24, 2026 | Volume: 101 | Issue: 6 | Pages: 680-687

10.1097/qai.0000000000003854 | PMID 41733274 Get It

Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are nephroprotective but are associated with early eGFR decline, also termed “eGFR dip.” Despite elevated risk of kidney disease, this phenomenon is understudied among people with HIV (PWH). Methods: In a 1:1 propensity score–matched cohort study using data from 9 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites, we compared new SGLT2i users with new users of other antihyperglycemic classes. We estimated adjusted hazard ratios (aHRs) for time to ≥10% and ≥30% eGFR decline using multivariable Cox proportional hazards models and analyzed eGFR change using multivariable linear mixed models. In addition, longer-term eGFR trends over 24 months were visualized using locally weighted scatterplot smoothing (LOWESS) curves. Results: Among 1554 eligible PWH, we obtained 295 matched pairs. Over 6 months, eGFR decline incidence of ≥10% and ≥30% was higher among users of SGLT2i versus other antihyperglycemic classes (58.2% vs. 37.4%; aHR: 1.79; 95% CI: 1.40%–2.28%; and 17.3% vs. 9.8%; aHR: 1.69; 95% CI: 1.05–2.73; respectively). The adjusted mean eGFR change at 6 months was −2.62 mL/min/1.73 m 2 for SGLT2i versus 0.05 mL/min/1.73 m 2 for other classes. Long-term eGFR trends revealed an expected initial decline after SGLT2i initiation, followed by stabilization and a slower subsequent decline compared with other classes. Conclusions: Acute eGFR dips were more common among PWH initiating SGLT2i relative to other antihyperglycemic classes, although overall declines were small, transient, and consistent with the general population. Further research is needed to explore the long-term effects of SGLT2i in PWH.
Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia
Douville, Christopher, Parksong, Jeeun , Molin, Marco Dal, Graham, Sarah , Greipp, Patricia T. , Knudson, Ryan A., Curtis, Samuel , Wang, Yuxuan , Dobbyn, Lisa , Popoli, Maria , Ptak, Janine , Silliman, Natalie , Romans, Katharine , Iacobuzio-Donahue, Christine A., Makoohon-Moore, Alvin P., Goggins, Michael, Hruban, Ralph H., Kiemen, Ashley, Bettegowda, Chetan, Kinzler, Kenneth W., Papadopoulos, Nickolas, Wood, Laura D, Vogelstein, B., Goggins, Michael , Hruban, Ralph H. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Bettegowda, Chetan , Douville, Christopher , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Wood, Laura D. , Molin, Marco Dal , Douville, Christopher , Dal Molin, Marco , Knudson, Ryan, Iacobuzio-Donahue, Christine A , Lennon, Anne Marie , Goggins, Michael G , Hruban, Ralph H , Kiemen, Ashley , Bettegowda, Chetan , Kinzler, Kenneth W , Papadopoulos, Nickolas , Wood, Laura D , Vogelstein, Bert , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Greipp, Patricia T , Vogelstein, Bert

Mayo Clinic

Science Advances | February 20, 2026 | Volume: 12 | Issue: 8 | Pages: No page available

10.1126/sciadv.adx7501 | PMID 41719404 Get It

We searched for oncogenes activated by copy number increases using whole-genome sequencing data of 535 pancreatic ductal adenocarcinomas (PDACs). We found that gains of 1q were the second most common gain, occurring in 213 (39.8%) of PDACs. Single-cell analysis via fluorescence in situ hybridization on 33 cancers confirmed these results. A portion of 1q, rather than the entire 1q arm, was gained in 75 (14.0%) PDACs, allowing us to pinpoint two ~3-megabase regions of 1q that were nearly always gained. These two regions contained NCSTN and PSEN2 , genes that code two subunits of the γ-secretase complex. Evaluation of 267 precancerous lesions revealed that extra copies of NCSTN and PSEN2 were common (49%) in noninvasive neoplasms (high-grade pancreatic intraepithelial neoplasms), which are at relatively high risk for progression to PDACs, but uncommon (6%) in low-grade pancreatic intraepithelial neoplasia lesions, which have low malignant potential. We hypothesize that γ-secretase genes are genetically activated oncogenes in the early phases of pancreatic neoplasia.